K. Hor and M. Taylor, Review: Suicide and schizophrenia: a systematic review of rates and risk factors, J Psychopharmacol, vol.24, pp.81-90, 2010.

M. Nordentoft, Absolute Risk of Suicide After First Hospital Contact in Mental Disorder, Arch Gen Psychiatry, vol.68, issue.10, p.1058, 2011.

J. Guelfi, R. Rouillon, and . Manuel-de-psychiatrie,

T. Anthonyj and B. G. Katzung, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review, 11e

J. De-leon, M. T. Susce, and E. Murray-carmichael, The AmpliChip TM CYP450 Genotyping Test. Mol Diag Ther. 1 mai, vol.10, issue.3, pp.135-51, 2006.

M. Ingelman-sundberg, Genetic polymorphisms of cytochrome P 450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity, Pharmacogenomics J. févr, vol.5, issue.1, pp.6-13, 2005.

J. De-leon, S. C. Armstrong, and K. L. Cozza, Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19, Psychosomatics. févr, vol.47, issue.1, pp.75-85, 2006.

Z. Desta, X. Zhao, J. Shin, and D. A. Flockhart, Clinical significance of the cytochrome P450 2C19 genetic polymorphism, Clin Pharmacokinet, vol.41, issue.12, pp.913-58, 2002.

D. W. Nebert, Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet, vol.56, pp.247-58, 1999.

R. Pazoki, D. Bochao, K. R. Lin, and . Van-eijk, Phenome-wide and Genomewide Analyses of Quality of Life in Schizophrenia

M. Ehrminger, M. Urbach, C. Passerieux, B. Aouizerate, F. Berna et al., Modeling the Longitudinal Effects of Insight on Depression, Quality of Life and Suicidality in Schizophrenia Spectrum Disorders: Results from the FACE-SZ Cohort, JCM. 10 août, vol.8, issue.8, p.1196, 2019.

A. Persson, S. C. Sim, S. Virding, N. Onishchenko, and G. Schulte, Ingelman-Sundberg M. Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene, Mol Psychiatry. juin, vol.19, issue.6, pp.733-774, 2014.

S. C. Sim, L. Nordin, T. Andersson, S. Virding, M. Olsson et al., Association between CYP2C19 polymorphism and depressive symptoms, Am J Med Genet B Neuropsychiatr Genet. sept, vol.153, issue.6, pp.1160-1166, 2010.

T. Anthonyj and B. G. Katzung, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review, 11e

C. Hiemke, N. Bergemann, H. W. Clement, A. Conca, J. Deckert et al., Consensus Guidelines for Therapeutic Drug Monitoring in Neuro psychopharmacology: Update, Pharmacopsychiatry. janv, vol.51, issue.1-02, pp.9-62, 2017.

D. A. Mrazek, Psychiatric pharmacogenomic testing in clinical practice, Dialogues Clin Neurosci, vol.12, issue.1, pp.69-76, 2010.

A. Llerena, P. Dorado, M. Peñas-lledó, E. Cáceres, and M. , De la Rubia A. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients, The pharmacogenomics journal. 1 déc, vol.7, pp.408-418, 2007.

F. Gaillard-bigot, Description du polymorphisme génétique des cytochromes P450 2C19 et 2D6 (CYP2C19 et CYP2D6) d'une large cohorte franc?aise de patients suivis en psychiatrie, vol.53, 2019.

S. R. Kay, A. Fiszbein, and L. A. Opler, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, vol.13, issue.2, pp.261-76, 1987.

C. Lançon, R. G. Llorca, P. M. Auquier, and P. , Validity and reliability of the Frenchlanguage version of the Positive and Negative Syndrome Scale (PANSS), Acta Psychiatr Scand. sept, vol.100, issue.3, pp.237-280, 1999.

D. Addington, J. Addington, and E. Maticka-tyndale, Assessing depression in schizophrenia: the Calgary Depression Scale, Br J Psychiatry Suppl. déc, issue.22, pp.39-44, 1993.

G. Reine, D. Bernard, P. Auquier, L. Fur, B. Lançon et al.,

, Encephale. févr, vol.26, issue.1, pp.52-61, 2000.

A. K. Daly, J. B. Leathart, S. J. London, and J. R. Idle, An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution, Hum Genet. mars, vol.95, issue.3, pp.337-378, 1995.

H. Fukushima-uesaka, Y. Saito, K. Maekawa, S. Ozawa, R. Hasegawa et al., Genetic variations and haplotypes of CYP2C19 in a Japanese population, Drug Metab Pharmacokinet. août, vol.20, issue.4, pp.300-307, 2005.

J. Blaisdell, H. Mohrenweiser, J. Jackson, S. Ferguson, S. Coulter et al., Identification and functional characterization of new potentially defective alleles of human CYP2C19, Pharmacogenetics. déc, vol.12, issue.9, pp.703-714, 2002.

J. D. Robarge, L. Li, Z. Desta, A. Nguyen, and D. A. Flockhart, The star-allele nomenclature: retooling for translational genomics, Clin Pharmacol Ther. sept, vol.82, issue.3, pp.244-252, 2007.

J. K. Hicks, J. R. Bishop, K. Sangkuhl, D. J. Müller, Y. Ji et al., Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors, Clin Pharmacol Ther. août, vol.98, issue.2, pp.127-161, 2015.

A. Gaedigk, S. D. Simon, R. E. Pearce, L. D. Bradford, M. J. Kennedy et al., The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype, Clin Pharmacol Ther. févr, vol.83, issue.2, pp.234-276, 2008.

A. Gaedigk, J. C. Dinh, H. Jeong, B. Prasad, and J. S. Leeder, Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics, Disponible sur, vol.17, 2018.

J. P. Selten, D. Wiersma, and R. J. Van-den-bosch, Discrepancy between subjective and objective ratings for negative symptoms, J Psychiatr Res. févr, vol.34, issue.1, pp.11-14, 2000.

R. Bottlender, T. Sato, C. Groll, M. Jäger, I. Kunze et al., Negative symptoms in depressed and schizophrenic patients: how do they differ?, J Clin Psychiatry. août, vol.64, issue.8, pp.954-962, 2003.

J. Mäkinen, J. Miettunen, M. Isohanni, and H. Koponen, Negative symptoms in schizophrenia: a review, Nord J Psychiatry, vol.62, issue.5, pp.334-375, 2008.

E. Clapham, R. Bodén, L. Brandt, E. G. Jönsson, S. Bahmanyar et al., Suicide Ideation and Behavior as Risk Factors for Subsequent Suicide in Schizophrenia: A Nested Case-Control Study, Suicide Life Threat Behav. août, vol.49, issue.4, pp.996-1005, 2019.

J. Kirchheiner, K. Nickchen, M. Bauer, M. Wong, J. Licinio et al., Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response, Mol Psychiatry. mai, vol.9, issue.5, pp.442-73, 2004.

M. M. Jukic, R. L. Smith, T. Haslemo, E. Molden, and M. Ingelman-sundberg, Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study, Lancet Psychiatry. mai, vol.6, issue.5, pp.418-444, 2019.

M. Jukic, N. Opel, J. Ström, T. Carrillo-roa, S. Miksys et al., Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment. Molecular Psychiatry, vol.22, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01798313

A. Llerena, G. Edman, J. Cobaleda, J. Benítez, D. Schalling et al., Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6, Acta Psychiatr Scand. janv, vol.87, issue.1, pp.23-31, 1993.

A. Llerena, M. Naranjo, F. Rodrigues-soares, E. M. Penas-lledó, H. Fariñas et al., Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations, Expert Opinion on Drug Metabolism & Toxicology. nov, vol.10, issue.11, pp.1569-83, 2014.

T. Hiroi, S. Imaoka, and Y. Funae, Dopamine formation from tyramine by CYP2D6, Biochem Biophys Res Commun. 28 août, vol.249, issue.3, pp.838-881, 1998.

A. Yu, J. R. Idle, L. G. Byrd, K. W. Krausz, A. Küpfer et al., Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6, Pharmacogenetics. mars, vol.13, issue.3, pp.173-81, 2003.

T. Niwa, T. Hiroi, D. Tsuzuki, S. Yamamoto, S. Narimatsu et al., Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6, Brain Res Mol Brain Res, vol.129, issue.1-2, pp.117-140, 2004.

A. Haduch and W. A. Daniel, The engagement of brain cytochrome P450 in the metabolism of endogenous neuroactive substrates: a possible role in mental disorders, Drug Metab Rev, vol.50, issue.4, pp.415-444, 2018.

E. G. Jönsson, M. L. Dahl, H. K. Roh, M. Jerling, and G. C. Sedvall, Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia, Psychiatr Genet, vol.8, issue.1, pp.25-33, 1998.

M. Pirmohamed, M. J. Wild, N. R. Kitteringham, K. O'brien, I. E. Buchan et al., Lack association between schizophrenia and the CYP2D6 gene polymorphisms, Am J Med Genet. 9 avr, vol.67, issue.2, pp.236-243, 1996.